Focus

Challenges of Blood Transfusions in β-Thalassemia during COVID-19 Pandemic in Low Middle-Income Country

Abstract

In China Hubei province, Wuhan was recognized as the focus of an epidemic of pneumonia of unidentified origin in December 2019. Ultimately, intense focus on the disease was raised worldwide and in China. as a result, on January 7, 2020, Chinese research scientists identified the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an affected patient in Wuhan.

Beta thalassemia is a congenital hereditary disorder of inefficient erythropoiesis that leads to peripheral red cell breakdown due to defective β-globin series. The severity of the disease depends on multiple genetic and environmental factors. Individuals with beta-thalassemia are classified based on their transfusion demands as having transfusion-dependent thalassemia (TDT) or non-transfusion-dependent thalassemia (NTDT). Routine transfusion remains the recommended standard management for beta-thalassemia, as it efficiently controls the thalassemia symptoms. If left untreated, Beta thalassemia major (BTM) can eventually induce spleen enlargement, deformation of bone because of bone marrow growth, and heart failure as a result of severe anemia.3, 4, 5, 6

1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181(2):271-280.e8.
2. World Health Organization. Coronavirus. Available from: https :www.who.int/healt h-topic s/coronavirus. Accessed 13 Feb 2020.
3. Olivieri NF. The beta-thalassemias, N Engl J Med. 1999 Jul 8;341(2):99-109.
4. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013;98(6):833-44.
5. Lal A, Wong TE, Andrews J, et al. Transfusion practices and complications in thalassemia. Transfusion 2018;58(12):2826-2835.
6. Rachmilewitz E, Giardina PJ. How I treat thalassemia. Blood 2011;118:3479–88.
7. Modell B, Darlison M. Global epidemiology of hemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480–7.
8. Cheraghali AM. Blood safety concerns in the Eastern Mediterranean region. Hepat Mon 2011;11(6):422-6.
9. Basak Aliz S, Yildirim M, Atunay H, Uluhan R, Canatan D. Effects of the problems faced by patients with thalassemia during supply of blood and blood transfusion. Vox Sang 2012;103(S1):77.
10. Schön born L, Weitmann K, Greger N, Kiefel V, Hoffmann W, Greinacher A. Longitudinal changes in the blood supply and demand in North-East-Germany 2005-2015. Transfus Med Hemother 2017;44:224–31.
11.Canatan D, Özsancak A. A new donor system for the patients with thalassemia: Blood mother and blood father. Asian J Transfus Sci 2010;4:109–11.
12. Choudhury N. Blood transfusion in borderless South Asia. Asian J Trans fus Sci 2011;5: 117–20.
13.Yasmeen H, Toma S, Killeen N, Hasnain S, Foroni L. The molecular characterization of beta globin gene in thalassemia patients reveals rare and a novel mutation in Pakistani population. Eur J Med Genet 2016;59(8):355-62.
Files
IssueVol 10, No 1 (Winter 2022) QRcode
SectionFocus
DOI https://doi.org/10.18502/jpc.v10i1.9128
Keywords
Blood transfusion COVID-19 β-thalassemia
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ali K, Rizvi K, Ansari SH, Zahid F. Challenges of Blood Transfusions in β-Thalassemia during COVID-19 Pandemic in Low Middle-Income Country. J Pharm Care. 2022;10(1):40-41.